Is Assembly Biosciences Inc (ASMB) overvalued? · rev $21.6M
Assembly Biosciences Inc (ASMB) is a biotechnology company listed on US.
This page asks whether Assembly Biosciences Inc (ASMB) looks expensive on cached numbers — not a short thesis.
Latest reported ASMB revenue for 2026-06-30 was $21.6M. Net income was -$12.9M. ASMB currently screens at market cap $143.0M.
ASMB currently screens at market cap $143.0M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ASMB 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ASMB stock page for the full model, not this heading.
Not investment advice.